Drug details

Briumvi (ublituximab-xiiy injection)

type of Antineoplastics, Anti-CD20 Monoclonal Antibodies

Briumvi (ublituximab-xiiy) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever,
• chills,
• headache,
• flu-like symptoms,
• sore throat, and
• abnormal blood values (reduction in Immunoglobins, Neutrophils)

The following drugs are related to Briumvi, either as a replacement or used together:

• Aubagio (teriflunomide tablets)
• Bafiertam (monomethyl fumarate delayed-release capsules)
• Mavenclad (cladribine tablets)
• Tecfidera (dimethyl fumarate delayed release capsules)
• Vumerity (diroximel fumarate delayed-release capsules)
• Gilenya (fingolimod capsules)
• Kesimpta (ofatumumab injection)
• Mayzent (siponimod tablets)
• Tyruko (natalizumab-sztn injection)
• Ocrevus (ocrelizumab injection)
• Zeposia (ozanimod capsules)
• Ponvory (ponesimod tablets)